NOVARTIS AG-SPONSORED ADR (NVS) Stock News
NYSE:NVS - New York Stock Exchange, Inc. - US66987V1098 - ADR - Currency: USD
NVS Latest News, Press Relases and Analysis
NOVARTIS AG-SPONSORED ADR (NYSE:NVS) is a prime example of a stock that offers more than what meets the eye in terms of fundamentals.
NOVARTIS AG-SPONSORED ADR has a stellar value proposition. NYSE:NVS not only scores well in profitability, solvency, and liquidity but also maintains a very reasonable price point.
Ionis Q1 Earnings and Sales Top Estimates, Stock Gains on Raised '25 View
IONS reports better-than-expected first-quarter results. The company raises its sales guidance for 2025 by more than 20% on the back of two new licensing deals.
Regulus Downgraded By Analysts After $1.7B Novartis Buyout Offer — Street Sees Limited Upside Ahead
Regulus Therapeutics shares surged after Novartis announced a $1.7 billion acquisition, but analysts downgraded the stock citing limited upside. Retail sentiment remained bullish, with speculation of a higher bid or FDA-driven gains.
Healthy Returns: Here are the drugmakers with new U.S. investments as Trump’s pharma tariffs loom
Tariff threats are fueling a new wave of U.S. manufacturing investments from the pharmaceutical industry.
Humana Does Not Alter 2025 Outlook Despite Sales Miss And Medicare Membership Decline
Humana Inc. (NYSE:HUM) on Wednesday posted a first-quarter adjusted EPS of $11.58, up from $7.23 a year ago, beating the consensus of $10.07. Humana sales increased from $29.6 billion to $32.11 billion, slightly missing the consensus of $32.22 billion. The revenue was driven by higher per-member Medicare and state-based contract premiums. The Medicare increase was primarily driven by an increased direct subsidy due to the Inflation Reduction Act (IRA) and membership growth in the company’s stand
Mentions: HUM
Humana Does Not Alter 2025 Outlook Despite Sales Miss And Medicare Membership Decline
Humana beat Q1 EPS estimates with $11.58, reaffirmed 2025 guidance, and outlined margin goals despite a drop in Medicare Advantage membership.
Mentions: HUM
Novartis To Buy US Kidney Drug Developer Regulus Therapeutics For Around $800 Million
Novartis to buy Regulus for $0.8 billion upfront with potential for $1.7B total based on ADPKD drug milestone; deal set to close in H2 2025.
Mentions: RGLS
AppLovin Stock Tumbles After Edgewater Research Cuts Estimates Citing Rising Competition
Edgewater noted that the mobile gaming macro environment appears to be decelerating gradually, while competition from both Meta and Alphabet is intensifying.
Why Novartis (NVS) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
The ‘joiner’ era of bank M&A has begun
In less than two weeks since the Capital One-Discover deal received sign-off, Columbia, Eastern and Cadence Bank have all announced deals. So have a host of smaller institutions.
Mentions: IP
Novartis to Buy Regulus Therapeutics for as Much as $1.7 Billion
Novartis AG agreed to buy US biotech Regulus Therapeutics Inc. in a deal that could be valued at up to $1.7 billion.
Mentions: RGLS
Is The Trade Desk, Inc. (TTD) a Stock That Should Double in 3 Years?
We recently published a list of the 30 Stocks That Should Double in 3 Years. In this article, we are going to take a look at where The Trade Desk, Inc. (NASDAQ:TTD) stands against other stocks that should double in 3 years. On April 25, Kari Firestone, Aureus Asset Management executive chairman and co-founder, joined […]
5 HR pros on the move in April
From Hyatt Hotels Corp. to Caterpillar Inc., some of the country’s largest companies announced changes to their human resources leadership slate.
INCY Q1 Earnings & Revenues Beat Estimates on Higher Product Sales
Incyte reports better-than-expected first-quarter 2025 results, beating both earnings and revenue estimates, driven by strong Jakafi and Opzelura sales.
Compared to Estimates, Novartis (NVS) Q1 Earnings: A Look at Key Metrics
Although the revenue and EPS for Novartis (NVS) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Novartis Beats on Q1 Earnings and Sales, Raises Guidance, Stock Up
NVS' first-quarter earnings and sales beat estimates. Based on the strong momentum of its key drugs, the company raises its annual guidance. Share price rises.
Mentions: PFE
Novartis Creeps Toward A Breakout On Its Beat-And-Raise
Shares are consolidating and are now trading above their 50-day and 200-day lines.
US Stock Futures Edge Higher Tuesday: Expert Warns Of 'Perfect Volatility Storm' With Major Earnings And Economic Data Due This Week
U.S. stock futures rose Tuesday morning as investors looked ahead to upcoming earnings reports and awaited greater market clarity throughout the week. Things haven’t moved all that much on the trade and tariffs front, with Treasury Secretary Scott Bessent merely stating on Monday that it was up to China to “de-escalate” trade tensions. Bessent also hinted at a potential trade deal with India, saying that “it would be one of the first deals we would sign,” which investors will be watching closely
Trump's Auto Tariff Reprieve & Carney's Liberals Win Canada Election | Daybreak Europe 04/29/2025
Bloomberg Daybreak Europe is your essential morning viewing to stay ahead. Live from London, we set the agenda for your day, catching you up with overnight markets news from the US and Asia. And we'll tell you what matters for investors in Europe, giving you insight before trading begins. On today's show, Canadian Prime Minister Mark Carney is projected to win the nation's election, after a campaign dominated by President Donald Trump's tariffs. Carney's Liberals are on track to win enough seats to form at least a minority government. President Donald Trump is set to blunt the pain of tariffs affecting the auto industry, with a lifting of some levies on foreign parts for cars made in the US. Meanwhile, most power has now been restored in Spain following a massive electricity outage across the country and in neighboring Portgual. Today's Guests: Volvo cars CEO Håkan Samuelsson & Deutsche Bank CFO James von Moltke (Source: Bloomberg)
Novartis posts better-than-expected first-quarter sales, raises full-year guidance
Swiss pharmaceutical firm Novartis on Tuesday reported better-than-expected first-quarter sales and raised its full-year guidance.
Mentions: LLY
Our first move in this overbought market — plus Palo Alto makes a small buy
Every weekday, the Investing Club releases the Homestretch; an actionable afternoon update just in time for the last hour of trading.
Nvidia, Visa, Domino's, NXP: Stocks to watch today
U.S. stocks were on track for a flat to slightly lower open Monday as investors geared up for a jam-packed week of earnings spanning pizza chains, semiconductor makers, and sanitation giants.
3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S.
See these three top-10 stocks in the pharmaceutical industry that are pledging investment in the United States totalling over $100 billion.
The Smartest International Stock ETF to Buy With $100 Right Now
It could be time for international stocks to shine, making this ETF a must-own.
The Smartest International Stock ETF to Buy With $100 Right Now
It could be time for international stocks to shine, making this ETF a must-own.
These 2 Top Dividend Stocks Are Making Moves to Avoid the Impact of Tariffs: Are They Buys?
Mentions: JNJ
These 2 Top Dividend Stocks Are Making Moves to Avoid the Impact of Tariffs: Are They Buys?
President Donald Trump's macroeconomic policies are taking center stage on Wall Street. The 47th U.S. president has decided to implement aggressive tariffs on imported goods from most countries, although he recently paused these plans for 90 days. Regardless, corporations are looking for ways to avoid paying these tariffs.
Amgen to expand Ohio biotech manufacturing plant
(Reuters) -Amgen on Friday announced a $900 million expansion of its Ohio biotech manufacturing facility, becoming the latest in a string of drugmakers pledging to increase U.S. capacity amid Trump administration threats of potential import tariffs. Amgen, based in Thousand Oaks, California, said the plans bring its total investment in central Ohio to more than $1.4 billion, creating 750 jobs. Other drugmakers committing recently to U.S. manufacturing expansions include Eli Lilly, Novartis, Roche, and Johnson & Johnson.